The CCAAT box binding transcription factor, nuclear factor-Y (NF-Y) regulates transcription of human aldo-keto reductase 1C1 (AKR1C1) gene

Gene

Volumn 459, Issue 1-2, 2010, Pages 11-23

  Pallai, Rajash ^a   Simpkins, Henry ^b,c   Chen, Jianli ^b,c   Parekh, Hemant K ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^c STATEN ISLAND UNIVERSITY HOSPITAL   (United States)

Author keywords

Dihydrodiol dehydrogenase; Hydroxysteroid dehydrogenase; Liver hepatoblastoma; Lung adenocarcinoma; Ovarian carcinoma; Promoter regulation

Indexed keywords

20ALPHA HYDROXYSTEROID DEHYDROGENASE; CCAAT BINDING FACTOR; CISPLATIN; DIHYDRODIOL DEHYDROGENASE; NUCLEAR FACTOR Y;

ARTICLE; CANCER CELL CULTURE; CELL STRAIN HEPG2; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA FLANKING REGION; FEMALE; GEL MOBILITY SHIFT ASSAY; GENE DELETION; GENE IDENTIFICATION; GENE REPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; LIVER CARCINOMA; LUNG CARCINOMA; MOLECULAR CLONING; MUTAGENESIS; NUCLEOTIDE SEQUENCE; OVARY CARCINOMA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; TATA BOX; TRANSCRIPTION REGULATION;

20-HYDROXYSTEROID DEHYDROGENASES; ANTINEOPLASTIC AGENTS; BINDING SITES; CCAAT-BINDING FACTOR; CHROMATIN IMMUNOPRECIPITATION; CISPLATIN; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MUTAGENESIS, SITE-DIRECTED; OVARIAN NEOPLASMS; PROMOTER REGIONS, GENETIC; REGULATORY SEQUENCES, NUCLEIC ACID; RNA, SMALL INTERFERING; SEQUENCE DELETION; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 77952887361     PISSN: 03781119     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gene.2010.03.006     Document Type: Article

References (54)

1. Barski O.A., Gabbay K.H., Bohren K.M. Characterization of the human aldehyde reductase gene and promoter. Genomics 1999, 60:188-198.
2. Bi W., Wu L., Coustry R., de Crombrugghe B., Maity S.N. DNA binding specificity of the CCAAT-binding factor CBF/NF-Y. J. Biol. Chem. 1997, 272:26562-26572.
3. Bucher P. Weight matrix description of four eukaryotic RNA polymerase II promoter elements derived from 502 unrelated promoter sequences. J. Mol. Biol. 1990, 212:563-578.
4. Burczynski M.E., Lin H.K., Penning T.M. Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs). Electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase. Cancer Res. 1999, 59:607-614.
5. Caretti G., Motta M.C., Mantovani R. NF-Y associates with H3-H4 tetramers and octamers by multiple mechanisms. Mol. Cell. Biol. 1999, 19:8591-8603.
6. Chen Y.J., et al. Overexpression of dihydrodiol dehydrogenase is associated with cisplatin-based chemotherapy resistance in ovarian cancer patients. Gynecol. Oncol. 2005, 97:110-117.
7. Ciaccio P.J., Jaiswal A.K., Tew K.D. Regulation of human dihydrodiol dehydrogenase by Michael acceptor xenobiotics. J. Biol. Chem. 1994, 22:15558-15562.
8. Ciaccio P.J., Walsh E.S., Tew K.D. Promoter analysis of a human dihydrodiol dehydrogenase. Biochem. Biophys. Res. Commun. 1996, 228:524-529.
9. Deng H.B., Parekh H.K., Chow K.C., Simpkins H. Increased expression of dihydrodiol dehydrogenase induces resistance to cisplatin in human ovarian carcinoma cells. J. Biol. Chem. 2002, 17:15035-15043.
10. Deng H.B., Adikari M., Parekh H.K., Simpkins H. Ubiquitous induction of resistance to platinum drugs in human ovarian, cervical, germ-cell and lung carcinoma tumor cells overexpressing isoforms 1 and 2 of dihydrodiol dehydrogenase. Cancer Chemother. Pharmacol. 2004, 54:301-307.
11. Dorn A., Bollekens J., Staub A., Benoist C., Mathis D. A multiplicity of CCAAT box-binding proteins. Cell 1987, 50:863-872.
12. Dufort I., Soucy P., Labrie F., Luu-The V. Molecular cloning of human type 3 3α-hydroxysteroid dehydrogenase that differs from 20α-hydroxysteroid dehydrogenase by seven amino acids. Biochem. Biophys. Res. Commun. 1996, 228:474-479.
13. Goldsmith M.E., Madden M.J., Morrow C.S., Cowan K.H. A Y-box consensus sequences is required for basal expression of the human multidrug resistance (mdr1) gene. J. Biol. Chem. 1993, 268:5856-5860.
14. Higaki Y., et al. Molecular characterization of two monkey dihydrodiol dehydrogenases. Drug Metab. Pharmacokinet. 2002, 17:348-356.
15. Hsu N.Y., et al. Overexpression of dihydrodiol dehydrogenae as a prognostic marker of non-small cell lung cancer. Cancer Res. 2001, 61:2727-2731.
16. Huang H.-S., Jiunn C., Chang W.-C. The CCAAT box binding factor NF-Y is required for the expression of phospholipid hydroperoxide glutathione peroxidase in human epidermoid carcinoma A431 cells. FEBS Letters 1999, 455:111-116.
17. Hung C.F., Penning T.M. Members of the nuclear factor 1 transcription factor family regulate rat 3α-hydroxysteroid/dihydrodiol dehydrogenase (3α-HSD/DD AKR1C9) gene expression: a member of the aldo-keto reductase superfamily. Mol. Endocrinol. 1999, 13:1704-1717.
18. Hung J.J., Chow K.C., Wang H.W., Wang L.S. Expression of dihydrodiol dehydrogenase and resistance to chemotherapy and radiotherapy in adenocarcinoma cells of lung. Anticancer Res. 2006, 26:2949-2956.
19. Hyndman D.R., Dauman D.R., Heredia V.V., Penning T.M. The aldo-keto reductase superfamily homepage. Chem-Biol. Inter. 2003, 143:621-631.
20. Ji Q., Chang L., VanDenBerg D., Stanczyk F.Z., Stolz A. Selective reduction of AKR1C2 in prostrate cancer and its role in DHT metabolism. Prostate 2003, 54:275-289.
21. Ji Q., Aoyama C., Chen P.K., Stolz A., Liu P. Localization and altered expression of AKR1C family members in human ovarian tissues. Mol. Cell. Probes 2005, 19:231-226.
22. Jin Y., Penning T.M. Aldo-keto reductases and bioactivation/detoxification. Annu. Rev. Pharmacol. Toxicol. 2007, 47:263-292.
23. Jump D.B., Badins M.V., Thelen A. The CCAAT box binding factor, NF-Y, is required for thyroid hormone regulation of rat liver S14 gene transcription. J. Biol. Chem. 1997, 272:27778-27786.
24. Kabe Y., Yamada J., Uga H., Yamaguchi Y., Wada T., Handa H. NF-Y is essential for the recruitment of RNA polymerase II and inducible transcription of several CCAAT box-containing genes. Mol. Cell. Biol. 2005, 25:512-522.
25. Kam K.-Y., Jeong K.-H., Norwitz E.R., Jorgensen E.M., Kaiser U.B. Oct-1 and nuclear factor Y bind to the SURG-1 element to direct basal and gonadotropin releasing hormone (GnRH)-stimulated mouse GnRH receptor gene transcription. Mol. Endocrinol. 2005, 19:148-162.
26. Lamb K.A., Johnson L.R., Rizzino A. NF-Y binds to the CCAAT box motif of the FGF-4 gene and promotes FGF-4 expression in embryonal carcinoma cells. Mol. Reprod. Dev. 1997, 48:301-309.
27. Lee E.K., Regenold W.T., Shapiro P. Inhibition of aldose reductase enhances HeLa cell sensitivity to chemotherapeutic drugs and involves activation of extracellular signal-regulated kinases. Anticancer Drugs 2002, 13:859-868.
28. Lin H.K., Penning T.M. cloning, sequencing and functional analysis of the 5'-flanking region of the rat 3α-hydroxysteroid/dihydrodiol dehydrogenase gene. Cancer Res. 1995, 55:4105-4113.
29. cdc2 gene by cdc2 promoter binding factor/nuclear factor-Y in fetal rat ventricular myocytes. Circ. Res. 1998, 82:251-260.
30. Liu Z., et al. Structure and promoter characterization of aldo-keto reductase family 1 B10 gene. Gene 2009, 437:39-44.
31. Lou H., Du S., Ji Q., Stolz A. Induction of AKR1C2 by phase II inducers: identification of a distal consensus antioxidant response element regulated by Nrf2. Mol. Pharmacol. 2006, 69:1662-1672.
32. Mantovani R. A survey of 178 NF-Y binding CCAAT boxes. Nucleic Acid Res. 1998, 26:1135-1143.
33. Mantovani R., Li X.-L., Pessara U., van Huisjduijnen R.H., Benoist C., Mathis D. Dominant negative analogs of NF-YA. J. Biol. Chem. 1994, 32:20340-20346.
34. Matsuo N., et al. The transcription factor CCAAT-binding factor CBF/NF-Y regulates the proximal promoter activity in the human α1 (XI) collagen gene (COL11A1). J. Biol. Chem. 2003, 278:32763-32770.
35. Matuoka K., Chen K.Y. Nuclear factor Y (NF-Y) and cellular senescence. Exp. Cell Res. 1999, 253:365-371.
36. Nishizawa M., et al. Close kinship of human 20α-hydroxysteroid dehydrogenase gene with three aldo-keto reductase genes. Genes Cells 2000, 5:111-125.
37. Ozeki T., et al. Co-operative regulation of the transcription of human dihydrodiol dehydrogenase (DD)4/aldo-keto reductase (AKR)1C4 gene by hepatocyte nuclear factor (HNF)-4α and HNF-1α. Biochem. J. 2001, 355:537-544.
38. Penning T.M., Byrns M.C. Steroid hormone transforming aldo-keto reductases and cancer. Ann. N. Y. Acad. Sci. 2009, 1155:33-42.
39. Penning T.M., Burczynski M.E., Jez J.M., Hung C.F., Lin H.K. Human 3α-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation of male and female sex hormones. Biochem. J. 2000, 351:67-77.
40. Penning T.M., Steckelbroeck D.R., Bauman D.R. Aldo-keto reductase (AKR) 1C3: role in prostate disease and the development of specific inhibitors. Mol. Cell. Endocrinol. 2006, 248:182-191.
41. Sasano H., Suzuki T., Miki Y., Moriya T. Intracrinology of estrogens and androgens in breast carcinoma. J. Steroid Biochem. Mol. Biol. 2008, 108:181-185.
42. Selga E., Noé V., Ciudad C.J. Transcriptional regulation of aldo-keto reductase 1C1 in HT29 human colon cancer cells resistant to methotrexate: role in the cell cycle and apoptosis. Biochem. Pharmacol. 2008, 75:414-426.
43. Stanbrough M., Bubley G.J., Ross K., Golub T.R., Rubin M.A. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 2006, 66:2815-2825.
44. Su M., Lee D., Ganss B., Sodek J. Stereochemical analysis of the functional significance of the conserved inverted CCAAT and TAT elements in the rat bone sialoprotein gene promoter. J. Biol. Chem. 2006, 281:9882-9890.
45. Sugiura N., Takishima K. Regulation of the gene promoter for extracellular signal-regulated protein kinase 2 by transcription factors NF-Y and Sp3. Biochem. J. 2000, 347:155-161.
46. Sun F., Xie Q., Ma J., Yang S., Chen Q., Hong A. NF-Y is required for basal activation and chromatin accessibility of FGFR2 promoter in osteoblast-like cells. J. Biol. Chem. 2009, 284:136-3147.
47. Suzuki Y.J., Agarwal B.B., Packer L. α-lipoic acid is a potent inhibitor of NF-κB activation in human T cells. Biochem. Biophys. Res. Commun. 1992, 189:1709-1715.
48. Torigoe T., et al. Cisplatin resistance and transcription factors. Curr. Med. Chem. 2005, 5:15-27.
49. van Wageningen S., Nikoloski G., Vierwinden G., Knops R., van der Reijden B.A., Jansen J.H. The transcription factor nuclear factor Y regulates the proliferation of myeloid progenitor cells. Haematologica 2008, 93:1580-1582.
50. Wang K., Bohren K.M., Gabbay K.H. Characterization of the human aldose reductase gene promoter. J. Biol. Chem. 1993, 268:16052-16058.
51. Wang L.S., Chow K.C., Wu Y.C., Lin T.Y., Li W.Y. Inverse expression of dihydrodiol dehydrogenase and glutathione-s-transferase in patients with esophageal squamous cell carcinoma. Int. J. Cancer 2004, 111:246-251.
52. Zhang D., Tai L.K., Wong Li., Chiu L.L., Sethi S.K., Koay E.S. Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer. Mol. Cell. Proteomics 2005, 4:1686-1696.
53. Zhang Y., et al. Transcriptional regulation of the human PNRC promoter by NFY in HepG2 cells. J. Biochem. 2008, 143:675-683.
54. Zhou D., Masri S., Ye J.J., Chen S. Transcriptional regulation of the mouse PNRC2 promoter by the nuclear factor Y (NFY) and E2F1. Gene 2005, 361:89-100.